¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Chain Drug Rev"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • awaking drug control law
    °¢¼ºÁ¦Á¶Àý¹ý
  • adrenergic drug
    ¾Æµå·¹³¯¸°ÀÛ¿ë¾à
  • adverse drug reaction
    ¾à¹°À¯ÇعÝÀÀ
  • crude drug
    »ý¾à
  • cutaneous drug reaction
    ÇǺξ๰¹ÝÀÀ
  • cytotoxic drug
    ¼¼Æ÷µ¶¼º¾à¹°
  • drug
    1. ¾à, ¾à¹° 2. ¾àÁ¦
  • drug abstinence
    ¾à¹°±Ý´Ü
  • drug abuse
    ¾à¹°³²¿ë
  • drug acne
    ¾à¹°¿©µå¸§
  • drug addiction
    ¾à¹°Áßµ¶, ¾à¹°Å½´Ð
  • drug adjuvant
    ¾à¹°º¸Á¶Á¦, º¸Á¶¾à¹°
  • drug adsorption
    ¾à¹°ÈíÂø
  • drug allergy
    ¾à¹°¾Ë·¹¸£±â
  • drug delivery system
    ¾à¹°Àü´Þü°è
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • autonomic drug
    ÀÚÀ²½Å°æ¾à
  • awaking drug control law
    °¢¼ºÁ¦Á¶Àý¹ý
  • drug abstinence
    ¾à¹°±Ý´Ü, ±Ý´Ü
  • drug abuse
    ¾à¹°³²¿ë
  • drug acne
    ¾à¹°¿©µå¸§
  • drug addiction
    ¾à¹°Áßµ¶
  • drug adjuvant
    ÀǾàǰ÷°¡¹°
  • drug adsorption
    ¾à¹°ÈíÂø
  • drug allergy
    ¾à¹°¾Ë·¹¸£±â
  • drug-induced hemolytic anemia
    ¾à¹°À¯¹ß¿ëÇ÷ºóÇ÷
  • new drug application
    ½Å¾àÇã°¡½Åû
  • drug resistant bacterium
    ¾àÁ¦³»¼º±Õ
  • chemotherapeutic drug monitoring
    È­Çпä¹ý¾àÁ¦°¨½Ã
  • cognitive-acting drug
    ÀÎÁö±â´ÉȰ¼ºÁ¦
  • common drug
    º¸Åë¾à
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • antithyroid drug
    Ç×°©»ó¼±¾à(¡­å·).
  • antituberculosis drug
    Ç×°áÇÙ¾à(Á¦)
  • antiviral agent =a. drug
    Ç×¹ÙÀÌ·¯½º¾à, Ç×¹ÙÀÌ·¯½º¹°Áú, Ç×¹ÙÀÌ·¯½ºÀÎÀÚ.
  • application of drug in root canal
    ±Ù°ü÷¾à¹ý(ÐÆÎ·ôäå·Ûö).
  • arsenic drug
    ºñ¼Ò¾à(Ý÷áÈå·).
  • hallucinogenic drug See hallucinogen
    ȯ°¢Á¦(ü³ÊÆð¥)
  • hematinic drug
    Á¶Ç÷¾à(ðãúìå·).
  • hematological drug
    Ç÷¾×ÀÛ¿ë¾à(úìäûíÂéÄå·).
  • hydrophilic drug
    Ä£¼ö¼º ¾àÁ¦.
  • ideosyncratic drug response
    ƯÀ̼º ¾à¹° ¹ÝÀÀ
  • photoallergic drug eruption
    ±¤¾Ë·¹¸£±â¼º ¾àÁø
  • prescription drug
    󹿾à.
  • pressor drug
    Ç÷¾Ð»ó½ÂÁ¦.
  • prolonged action drug
    Áö¼Ó¼º ¾àÁ¦(ò¥áÙàõå·ð¥).
  • prolonged action drug
    Ưȿ¼º ¾àÁ¦(÷åüùàõå·ð¥), Áö¼Ó¼º ¾àÁ¦(ò¥áÙàõå·ð¥).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • mu heavy chain disease
  • mu-chain disease
    Mu-¼â º´(¡­ Ü»)
  • multiple chain
    º¹½Ä(ÜÜãÒ)»ç½½.
  • nuclear chain
    Çٻ罽, ÇÙ¼â(ú·áð).
  • nuclear chain fiber
    Çٻ罽±ÙÀ°¼¼Æ÷
  • open chain compound
    ¿­¸°»ç½½È­ÇÕ¹° °³¼âÈ­ÇÕ¹°(ËÒáðûùùêÚª) .
  • open chain form
    ¿­¸°»ç½½Çü.
  • ossicular chain
    À̼Ұñ¿¬¼â, °í½ÇÀÛÀº»À°í¸®{ÇØ}
  • ossicular chain reconstruction
    À̼Ұñ¿¬¼âÀç°Ç
  • oxidative chain
    »êÈ­¿¬¼â.
  • polymerase chain reaction
    ÁßÇÕÈ¿¼Ò ¿¬¼â¹ÝÀÀ
  • polymerase chain reaction
    Á¾ÇÕÈ¿¼Ò¿¬¼â¹ÝÀÀ
  • polymerase chain reaction
    ÁßÇÕÈ¿¼Ò¿¬¼â¹ÝÀÀ
  • polymerase chain reaction (PCR)
    ÁßÇÕÈ¿¼Ò ¿¬¼â ¹ÝÀÀ
  • polymerase chain reaction(PCR)
    ÁßÇÕ ¿¬¼â ¹ÝÀÀ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • open chain
    ¿­¸° »ç½½
  • parallel chain
    ÆòÇà(øÁú¼) »ç½½
  • P-K chain
    P-K »ç½½
  • polymerase chain reaction
    ÁßÇÕÈ¿¼Ò ¿¬¼â¹ÝÀÀ(ñìùêý£áÈÖ§áðÚãëë)
  • Porod-Kratky chain
    Æ÷·Îµå-Å©¶óŰ »ç½½
  • random flight chain
    ¹«ÀÛÁ¤ ¿¬°á(ÙííÂïÒÖ§Ì¿) »ç½½
  • random walk chain
    ¹«ÀÛÁ¤ ¿¬°á(ÙííÂïÒÖ§Ì¿) »ç½½
  • respiratory chain
    È£Èí ¿¬¼â(Ö§áð)
  • respiratory chain phosphorylation
    È£Èí¿¬¼â ÀλêÈ­(×òß«ûù)
  • side chain
    °ç°¡Áö
  • side chain cleavage
    °ç°¡Áö Àý´Ü(ï·Ó¨)
  • side chain theory
    °ç°¡Áö ÀÌ·Ð(×âÖå)
  • straight chain
    °ðÀº »ç½½
  • triple-chain length
    »ï(ß²)»ç½½ ±æÀÌ
  • two-genes-one-polypeptide chain
    ÀÌÀ¯ÀüÀÚ(ì£ë¶îîí­)- ÀÏ(ìé)Æú¸®ÆéŸÀÌµå »ç½½
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 5
PCR Polymerase Chain Reaction
SCC   1) Sude Chain-Cleavage Complex
  2) Squamous Cell Carcinoma
VLCFA Very Long Chain Fatty Acids
BCAA branched chain amino acid
BCKA branched-chain keto acid
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 5
DIC Drug Information Center
DRP Drug Related Problems
D.U.E. Drug Use Evaluation
DUR Drug Use Review
DUR Drug Utilization Review
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • drug induced
    ¾à¹° À¯¹ß¼º
  • drug induced disorder
    ¾à¹° À¯¹ß¼º Áúȯ
  • drug industry
    ¾à¹° Á¦¾à °ø¾÷
  • drug interference
    ¾à¹° °£¼·
  • drug metabolism
    ¾à¹° ´ë»ç
  • drug misuse
    ¾à¹° ¿À¿ë
    ¾à¹°À» ºÎÀûÇÕÇÏ°Ô »ç¿ëÇÏ¿© »ý±â´Â Áõ»óÀ¸·Î ¾à¹° ³²¿ë
  • drug of choice
    ¼±Åà ¾àÁ¦, Ưȿ ¾à
  • drug overload
    ¾à¹° °ú·® º¹¿ë
  • drug potentialization
    ¾à¹° »ó½Â, ¾à¹° »ó½Â ÀÛ¿ë
  • drug prophylaxis
    ¾àÁ¦ ¿¹¹æ
  • drug rash
    ¾à¹°¼º ¹ßÁø, ¾àÁø
  • drug receptor
    ¾à¹° ¼ö¿ëü
  • drug resistance factor
    ¾àÁ¦ ³»¼º ÀÎÀÚ
  • drug resistance transfer factor
    ¾àÁ¦ ³»¼º Àü´Þ ÀÎÀÚ
  • drug shock
    ¾à¹° Ãæ°Ý
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
immunoglobulins, j-chain The immunoglobulin fragments found in the light chain fractions of secretory IgA and polymeric IgM in a ratio of one j chain per one IgA dimer or one IgM pentamer. It is a polypeptide with a molecular weight of about 17 kD and probably serves either to bind the components of the globulins together or to transfer the globulins across membranes.
(12 Dec 1998)
immunoglobulins, kappa-chain One of the light chains of the immunoglobulins with a molecular weight of approximately 22 kD. They constitute about 60% of all light chains and can be recognised serologically as well as by their specific amino acid sequence.
(12 Dec 1998)
immunoglobulins, lambda-chain One of the light chains of the immunoglobulins with a molecular weight of approximately 22 kD. They constitute about 40% of all light chains and can be recognised serologically as well as by their specific amino acid sequence.
(12 Dec 1998)
immunoglobulins, light-chain Polypeptide chains, consisting of 211 to 217 amino acid residues, isolated from immunoglobulins and having a molecular weight of approximately 22 kD. There are two major types of light chains, kappa and lambda. In man they are found in a ratio of 60% to 40%, respectively. Both chains consist of linear repeating, similar, but not identical, segments of about 110 amino acid residues. In each segment a disulfide bond establishes a tightly folded approximately 60-membered loop or domain. Adjacent domains are linked by less tightly folded regions. Both light chains contain two such domains. Two light and two heavy chains make one immunoglobulin molecule, but both light chains in one ig are of the same type.
(12 Dec 1998)
immunoglobulins, mu-chain Heavy chains found in the fab and fc fragments of IgM and having a molecular weight of approximately 72 kD. They contain about 57 amino acid residues arranged in five domains and have more oligosaccharide branches and a higher carbohydrate content than the heavy chains of IgG.
(12 Dec 1998)
invariant chain <chemical> Noncovalently associated with class II antigens, alpha and beta chain complex; involved in the regulation of malignant cell ia function; iip31 and iip33 were synthesized by using alternative initiator methionines
Synonym: II igc, ia-associated invariant chain, II invariant glycoprotein complex, class II-associated invariant chain, IIp33, IIp31, clip peptide, ln-2 antigen, ln 2 antigen, cd74 antigen, II-key, II76-92
(05 Dec 1998)
open chain compound An organic compound in which the chain does not form a ring.
Synonym: aliphatic compound, open chain compound.
(05 Mar 2000)
ossicular chain The small bones of the middle ear; they are articulated to form a chain for the transmission of sound from the tympanic membrane to the oval window.
Synonym: ossicula auditus, ear bones, ossicular chain.
(05 Mar 2000)
EDTA light chain <protein> Myosin light chains (18 kD) from scallop muscle (two per pair of heavy chains), easily extracted by calcium chelation. Although the EDTA light chains do not bind calcium they confer calcium sensitivity on the myosin heavy chains.
(18 Nov 1997)
electron transport chain <biochemistry, chemistry> A series of compounds that transfer electrons to an eventual donor with concomitant energy conversion.
One of the best studied is in the mitochondrial inner membrane, that takes NADH (from the tricarboxylic acid cycle) or FADH and transfers electrons via ubiquinone, cytochromes and various other compounds, to oxygen. Other electron transport chains are involved in photosynthesis.
(18 Nov 1997)
J chain <molecular biology> A polypeptide chain (15 kD), found in IgA and in IgM joining heavy chains (H chains) to each other to form dimers of IgA and pentamers of IgM. Disulphide bonds are formed between the J chain and H chains near the Fc ends of the heavy chains. Despite the similar name, it is not identical with the J region or coded for by the J gene.
Synonym: J piece.
(10 Jan 1998)
kappa chain <protein> Either of two types of light chains (small polypeptide chains) that are found in immunoglobulins.
(09 Oct 1997)
2-methyl branched-chain enoyl-CoA reductase <enzyme> Important in the reversal of beta-oxidation under anaerobic conditions in ascaris suum
Registry number: EC 1.3.1.52
Synonym: 2-methyl bce-CoA reductase
(26 Jun 1999)
lambda chain <immunology> Although light chains are found in many multimeric proteins, L chain usually refers to the light chains of immunoglobulins.
These are of 22 kD and of one of two types, kappa or lambda. A single immunoglobulin has identical light chains (2 kappa or 2 lamda). Light chains have one variable and one constant region. There are isotype variants of both kappa and lamda.
(25 Jun 1999)
lauric acid in-chain-hydroxylase <enzyme> Specific for lauric acid; hydroxylates at c-8, c-9 or c-10 of chain
Registry number: EC 1.14.14.-
Synonym: (cytochrome p-450)-dependent laurate in-chain-hydroxylase
(26 Jun 1999)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 11 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • daisy chain
    µ¥ÀÌÁö ȭȯ;ÁÙÁÙÀÌ À̾îÁø °Í;(»ç°Ç,Ç׸ñ,´Ü°è µîÀÇ)¿¬¼â
  • door chain
    µµ¾ð üÀÎ(¹æ¹ü¿ë ¹®ÀÇ ¼è»ç½½)
  • drag chain
    (±â)¹ÙÄû ¸ØÃß´Â ¼è»ç½½;(Â÷·®ÀÇ)¿¬°á »ç½½;(ºñÀ¯)Àå¾Ö¹°;¹æÇع°
  • fission chain reaction
    Çٺп­ ¿¬¼â ¹ÝÀÀ
  • fob chain
    ½Ã°èÁÙ(²ö,¸®º»)
  • food chain 1
    ¸ÔÀÌ¿¬¼â;½Ä·áǰ ¿¬¼âÁ¡
  • guard chain
    (½Ã°è µûÀ§ÀÇ)»ç½½ÁÙ
  • heavy chain
    (¸é¿ª ±Û·ÎºÒ¸°ÀÇ)Áß¿¬¼â
  • light chain
    Àü±â ½ºÅĵåÀÇ ²ö
  • mountain chain
    »ê¸Æ
  • watch chain
    ȸÁß ½Ã°èÀÇ ¼èÁÙ
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 5
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 5
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 5
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 5
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 5
ÅëÇÕ°Ë»ö ¿Ï·á